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1. Introduction
  Glaucoma is a severe optic neuropathy. Lack of treatment 
can lead to blindness of the patients with it. There are about 
70 million people influenced by this disease all around the 
world[1]. This kind of cryptogenic disease, the main reason 
of irreversible blindness, is with increased intraocular 
pressure due to a resistance in the trabecular meshwork 
outflow pathway of aqueous humor[2]. Eye drops treating 
glaucoma usually contain a preservative, benzalknium 
chloride (BAK), a quaternary ammonium salt composed 
of a mixture of benzododecinium C21H38N
+
(BAK C12) and 
myristalkonium C23H42N
+
(BAK C14) chlorides.
  Studies have showed that BAK-free eye drops have 
favorable IOP-lowering effect[3], but this clinical result 
lacks theoretical evaluation and data research. This paper 
explores the safety and effectiveness of BAK-free eye drops 
in treating glaucoma and ocular hypertension with Meta 
analysis and also emphasize on the exploration of the toxic 
effects of BAK on endothelial cells, cornea and other cells 
constituting the intraocular microenvironment.
 
2. Materials and methods
2.1. Research objectives
  The clinical case-control literatures about eye drops (with/
without BAK) treating glaucoma and ocular hypertension 
were retrieved in PubMed, EMBASE, Cochrane and CBM 
database. The data were sourced from the published 
literatures in the database. The main search items included 
BAK, glaucoma, high intraocular pressure, adverse effect, 
etc. The publication time is from 2003 to 2010.
Objective: To explore the safety and efficacy of eye drops without benzalkonium chloride (BAK) 
in treating glaucoma and ocular hypertension. Methods: The clinical case-control literatures 
about eye drops without BAK treating glaucoma and ocular hypertension were retrieved in 
PubMed, EMBASE, Cochrane and Chinese Biological and Medical database. Meta 5.0 software was 
used to analyze the literatures. Results: Five clinical control studies were included. The results 
indicated both eye drops could lower the intraocular pressure, and the intraocular pressure-
lowering difference between two eye drops was 0.07 mmHg (95% CI: 0.04, 0.19) (P>0.05). Two 
adverse reactions occurred more were conjunctival injection (10.78%) and allergic conjunctivitis 
(4.78%). The odd ratio of two eye drops occurring conjunctival injection and allergic conjunctivitis 
was 0.67 (95% CI, 0.25, 1.10) and 0.82 (95% CI, 0.09, 1.54), respectively (P<0.05) in fixed effect 
model. Conclusions: There is no difference between the eye drops with or without BAK in 
lowering intraocular pressure, but the latter is of higher safety. In consideration of the relatively 
small sample size of this research, more high-quality clinical research contrasts are needed as 
evidence.
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2.2. Classification standard of glaucoma 
  At present, in clinic, the classification of glaucoma in China 
was according to “Preliminary advice for early diagnosis of 
primary glaucoma” established in 1987, while in scientific 
research, ISGEO classification is adopted. Glaucoma is 
mainly divided into primary closed-angle glaucoma, open-
angle glaucoma, acute angle-closure glaucoma, etc.
2.3. Inclusive criteria
  The inclusive criteria of this research are as following: 
(i) Only the publicly published papers in the journals can 
be collected and selected; (ii) The research hypothesis and 
methods were similar; (iii) The research objects should be 
normal people; (iv) The detection result was expressed by 
mean and standard deviation; (v) All the clinical case control 
researches on the comparison between using eye drops 
containing BAK and using BAK-free eye drops were used in 
the therapeutic scheme. Factors like the age of the patient 
and intraocular pressure before operation were considered 
at grouping. Bias caused by human factor was excluded.
2.4. Exclusive criteria
  
  (i) Literatures containing duplicated data, study of own-
control before and after the treatment, and cohort study; (ii) 
Literatures can’t be used for poor quality, low information 
or incomplete data, like case reports; (iii) Original 
literatures without efficacy evaluation for the treatment; 
(iv) Unreasonable research design (unreasonable design of 
the control group, fuzzy description about the sample data, 
and none-standardized diagnosis or curative judgment); (v) 
Duplicate published literatures.
2.5. Statistical analysis
  All the literature data (including authors, publication time, 
cases of the objects, etc.) were input in the Review Manager 
5.0 software for the heterogeneity and Meta analysis. If 
no heterogeneity existed in each study (P曒0.1, I
2=0), 
fixed effect model was adopted; on the contrary, random 
effect model was adopted for the data analysis. Mantel-
Haenszel (fixed effect model) and DerSimonian and Laird 
method (random effect model) were used for the calculation 
of combined effect value. For all the statistical data, the 
statistical value of utility analysis was expressed by OR 
value, and the corresponding 95% CI was calculated. There 
was no statistical difference of the two therapeutic scheme 
when P<0.05.
3. Results
3.1. Information about the included literatures
  
  Seventy-eight related literatures were preliminarily 
retrieved according to the data collection methods and 
retrieval strategy. Five clinical control literatures published 
between 2003 and 2010 were finally included strictly 
according to the inclusive and exclusive criteria. Based on 
different research objectives, the patients with glaucoma, 
ocular hypertension, etc., who have to control IOP through 
long term use of medicine, were grouped according to 
equilibrium principle. The sample size of each research 
was between 80-780 eyes, and the follow-up time ranged 
from 3 weeks to 1 year. The basic information and quality 
evaluation of the included research are showed in Table 1. 
The included eyes of the five research were 1 549, 774 of 
which used eye drops containing BAK and 775 used BAK-
free eye drops. There was no statistical significance between 
the two groups in terms of age, sex, IOP before treatment, 
etc.  
3.2. IOP-lowering efficacy of eye drops with BAK and BAK-
free eye drops
3.2.1. Effectiveness evaluation of lowering IOP  
  All the five literatures reported the IOP of the research 
objects before treatment and in the follow-up period. The 
statistical value of the heterogeneity test was I2=0, P>0.1. 
Random effect model was adopted. The IOP-lowering 
Table 1
The basic information and quality evaluation of the included research. 
Authors 
Publication
time
Eyes 
(B/B-free)
Eye drops with BAK BAK-free eye drops
Follow-up time 
(month)
Quality
 evaluation
Mundorf et al[4] 2003 407(204/203) 0.2% Brimonidine 0.15% Brimonidine -Purite 3.0 3
Lewis et al[5] 2007 690(346/344) 0.004% Travoprost 0.004%Travoprost-BAKfree 3.0 3
Hamacher et al[6] 2008    85(42/43) 0.001 5 Tafluprost 0.001 5 Tafluprost-BAKfree 1.0 3
Gross et al[7] 2008   106(52/54) 0.004%Travoprost 0.004%Travoprost-BAKfree 0.5 3
Shedden et al[8] 2010 261(130/131) Fixed formula 2% Dorzolamide/0.5% 
Timolol
Fixed formula 2% Dorzolamide/0.5% 
Timolol-BAK free
3.0 3
In all studies, follow-up investigation was performed and the conditions were balanced. 
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difference between the patients using two kinds of eye drops 
was 0.07 mmHg (95% CI -0.04, 0.19) (P=0.07). IOP lowering 
was taken as the index to evaluate the efficacy of eye drops 
with and without BAK in treating glaucoma and ocular 
hypertension, and the result indicated that there was no 
significant difference between the efficacies of the two kinds 
of eye drops (Figure 1).
3.2.2. Potential publication bias
  Using IOP-lowering as the analysis index, the funnel 
plot was drawn. Due to the few included researches, the 
distribution tendency was unobvious, but the funnel plot 
was symmetric which meant the publication bias was small 
(Figure 2). 
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Figure 2. Funnel plot of the publication bias.
3.2.3. Adverse effect in the follow-up period  
  All the five literatures included in Meta analysis mentioned 
adverse effects in the follow-up period which included 
conjunctival injection, allergic conjunctivitis, dry eye, taste 
dysfunction, etc. The two most common adverse effects were 
conjunctival injection (10.78%) and allergic conjunctivitis 
(4.78%). The heterogeneity test of the adverse effect was 
P>0.1, I2<50%. Random effect model was adopted for the 
Meta analysis (Table 2). The results indicated that the 
percentage of patients developing conjunctival injection 
and allergic conjunctivitis using eye drops containing 
BAK were 0.67 and 0.82 times of those using BAK-free eye 
drops respectively (Pboth<0.05), which revealed the notable 
difference between the two kinds of eye drops in safety. The 
safety of eye drops containing BAK was better than those 
without BAK. The forest graph and funnel plot are shown in 
Figures 3-6 which indicated that the publication bias was 
small.
Table 2 
Adverse effect comparison in the follow-up period between eye drops 
with BAK and BAK-free eye drops (n=1 549).
Adverse effect OR (95% CI) P value
Conjunctival injection 0.67(0.25, 1.10) 0.002
Allergic conjunctivitis 0.82(0.09, 1.54) 0.030
Study of subgroup
BAK BAK-free
Weight (%)
Mean difference Mean difference
Mean SD Total Mean SD Total IV, Fixed, 95% CI IV, Fixed, 95% CI
Gross et al (2008) 0.47 0.86 204 0.44 0.88 203 47.2   0.03 [-0.14, 0.20]
Hamacher et al (2008) 0.73 1.84 346 0.62 1.57 344 20.7    0.11 [-0.15, 0.37]
Lewis et al (2007) 0.37 0.83   42 0.34 0.86   43 10.5    0.03 [-0.33, 0.39]
Mundorf et al (2003) 0.51 1.14   52 0.43 0.71   54 10.2    0.08 [-0.28, 0.44]
Shedden et al (2010) 0.66 1.48 130 0.45 1.36 131 11.3    0.21 [-0.13, 0.55]
Total (95% CI) 774 775      100.0   0.07 [-0.04, 0.19]
Heterogeneity Chi2=4.28, df=4 (P=0.37); I2=7%
Test for overall ellect: Z=3.10 (P=0.002)
Figure 1. Meta analysis of the IOP-lowering effect of patients using eye drops with BAK and BAK-free eye drops.
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Study of subgroup
BAK BAK-free
Weight (%)
Mean difference Mean difference
Mean SD Total Mean SD Total IV, Fixed, 95% CI IV, Fixed, 95% CI
Gross et al (2008) 1.93 1.37 26 0.37 2.28   14 10.7 1.56 [0.25, 2.87]
Hamacher et al (2008) 1.21 2.28 22 0.28 1.09   20 16.0   0.93 [-0.14, 2.00]
Lewis et al (2007) 2.36 2.61 36 1.48 1.01   32 21.4    0.88 [-0.04, 1.80]
Mundorf et al (2003) 1.74 1.67 38 1.23 1.41   34 35.8    0.51 [-0.20, 1.22]
Shedden et al (2010) 0.74 1.67 24 0.81 1.78   18 16.2  -0.07 [-1.13, 0.99]
Total (95% CI)      146 118      100.0  0.67 [0.25, 1.10]
Heterogeneity Chi2=4.28, df=4 (P=0.37); I2=7%
Test for overall ellect: Z=3.10 (P=0.002)
Figure 3. Meta analysis of conjunctival injection in patients using eye drops with BAK and BAK-free eye drops to lower IOP.
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Study of subgroup
BAK BAK-free
Weight (%)
Mean difference Mean difference
Mean SD Total Mean SD Total IV, Fixed, 95% CI IV, Fixed, 95% CI
Grosset et al (2008) 1.93 1.67 10 0.37 2.28   6 12.0 1.56 [-0.54, 3.66]
Hamacher et al (2008) 1.41 2.28 14 0.28 1.09   6 24.1   1.13 [-0.35, 2.61]
Lewls et al (2007) 2.36 2.61 20 1.18 1.01   8 29.4   1.18 [-0.16, 2.52]
Muncorf et al (2003) 0.74 1.67 12 0.63 1.41   4 18.8   0.11 [-1.56, 1.78]
Shedden et al (2010) 0.74 1.67   8 0.81 1.78   6 16.7 -0.07 [-1.91, 1.77]
Total (95% CI) 64 30      100.0 0.82 [0.09, 1.54]
Heterogeneity Chi2=4.28, df=4 (P=0.37); I2=7%
Test for overall ellect: Z=3.10 (P=0.002)
Figure 4. Meta analysis of allergic conjunctivitis in patients using eye drops with BAK and BAK-free eye drops to lower IOP.
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Figure 5. Funnel plot of the publication bias about conjunctival 
injection in patients using eye drops with BAK and BAK-free eye 
drops to lower IOP.
0
0.5
1.0
1.5
2.0
-10                 -5                    0                     5                   10
MD
SE (MD)
Figure 6. Funnel plot of the publication bias about allergic 
conjunctivitis in patients using eye drops with BAK and BAK-free eye 
drops to lower IOP.
4. Discussion
   In recent two decades, anti-glaucoma drug research has 
witnessed significant progress, which results in the increase 
of the options of drugs treating glaucoma. In this study, 
we analyzed five controlled clinical studies on eye drops 
with BAK and BAK-free eye drops treating glaucoma and 
ocular hypertension. We found that the main reason for the 
impact factor of glaucoma transferred from the previous IOP 
increase to current optic nerve damage was the two clinical 
conditions associated with glaucoma, that is, glaucoma 
with ocular hypertension and normal tension glaucoma. 
The compliance of the primary open angle glaucoma and 
eye hypertension patients in the treatment period would 
directly influence the prognosis[9,10]. At present, lowering 
the increased IOP is the only way proved feasible in clinic 
to prevent the visual impairment and the development of 
glaucoma[11,12].
  BAK has bacteriostasis and bactericidal effect, which had 
been widely used as the preservative of ophthalmic drugs 
since the end of the 1940s[13]. Studies of recent years have 
shown that the adverse reactions of IOP-lowering medication 
including conjunctival congestion and dryness are connected 
with the preservative, mainly BAK, in the medication[14,15]. A 
number of in vitro and in vivo experiments have confirmed 
that BAK can lead to patients’ adverse reactions through 
ways like increasing the inflammatory level in the tear, 
inducing the apoptosis of trabecular meshwork cells and 
generating toxic effect on corneal endothelial and epithelial 
cells[16-18]. Currently, over 70% eye drops on the market 
(including those against intraocular hypertension) contain 
BAK[19]. In addition, there is another preservative slfZia. It is 
an ionic buffer system containing borate, sorbitol, propylene 
glycol and zinc which could be used as the substitute of 
BAK. In this research, this ionic buffer system was used 
to replace the traditional preservative BAK in many BAK-
free eye drops. The results showed that the lack of BAK 
did not affect the IOP-lowering effect of these eye drops, 
however, their safety was worse than those containing 
BAK. Ryan et al designed an experiment to compare the 
antimicrobial activity of eye drops against intraocular 
hypertension containing these two preservatives[20]. Their 
research results indicated that although both the two eye 
drops accorded with the pharmacopoeia criterion of the 
United States and Japan, the bacteriostasis and bactericidal 
activity of eye drops containing BAK were notably better 
than those without BAK, which is close to the results of our 
research. The five literatures in this research reported the 
adverse reactions like conjunctival injection and allergic 
conjunctivitis. The analysis results indicated that the safety 
of eye drops containing BAK was better than those without 
BAK (P<0.05). The reason may lie in the superiority of the 
bactericidal activity of eye drops containing BAK over those 
without BAK. When patients were faced with contamination 
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and subsequent exposure to microorganisms during use, the 
former could provide a more protective environment.
  In short, the present results of the controlled clinical 
research indicated that there was no statistical significance 
between the IOP-lowering effect of BAK-free eye drops 
and eye drops containing BAK in treating glaucoma and 
eye hypertension, and the safety of eye drops containing 
BAK was higher. However, the literature sample size of this 
research was small, and more high-quality, prospective 
randomized controlled trials are still in need as the 
corroboration for this conclusion.
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